This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
Eli Lilly (LLY) closed at $827.54 in the latest trading session, marking a +1.16% move from the prior day.
Q1 Earnings Season Scorecard and Analyst Reports for NVIDIA, Alphabet & Berkshire Hathaway
by Sheraz Mian
Today's Research Daily features a real-time update on the Q1 earnings season, in addition to updated research reports on 16 major stocks, including NVIDIA (NVDA), Alphabet (GOOGL) and Berkshire Hathaway Inc. (BRK.B).
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
by Zacks Equity Research
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges
by Sanghamitra Saha
Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.
Strength Seen in Lilly (LLY): Can Its 14.3% Jump Turn into More Strength?
by Zacks Equity Research
Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
by Zacks Equity Research
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?
by Kinjel Shah
Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the most recent trading session, Eli Lilly (LLY) closed at $757.18, indicating a +0.38% shift from the previous trading day.
Pfizer Halts Obesity Pill Development Amid Safety Concerns
by Zacks Equity Research
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
by Zacks Equity Research
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
by Ahan Chakraborty
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?
by Kinjel Shah
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
The Zacks Analyst Blog Highlights Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri
by Zacks Equity Research
Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri are included in this Analyst Blog.
Top Research Reports for Eli Lilly, American Express & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), American Express Company (AXP) and Thermo Fisher Scientific Inc. (TMO), as well as two micro-cap stocks, Steel Partners Holdings L.P. (SPLP) and Oil-Dri Corporation of America (ODC).
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?
by Kinjel Shah
PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
by Ekta Bagri
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Eli Lilly (LLY) stood at $726.14, denoting a +0.33% change from the preceding trading day.
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?
by Kinjel Shah
Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.
AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis
by Zacks Equity Research
European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare
by Kinjel Shah
CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
by Sundeep Ganoria
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.